Literature DB >> 23032977

Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library.

Yoshiaki Miura1, Satoshi Yamasaki, Julia Davydova, Eric Brown, Kazunori Aoki, Selwyn Vickers, Masato Yamamoto.   

Abstract

Adenovirus (Ad) is a potent gene-delivery vehicle and has frequently been used for designing oncolytic viruses. However, lack of selectivity on infection has hampered the achievement of sufficient in vivo efficiency. Here, we developed a novel oncolytic virus system, infectivity-selective oncolytic adenovirus (ISOAd), via direct high-throughput screening of a high-diversity targeting-ligand library in adenoviral format. Through our newly designed rescue virus system, the high-diversity Ad library carrying the random seven amino acid sequences ligand-library in the AB-loop of its fiber-knob region (5 × 10(9) diversity) was successfully generated. During the screening of this library with the cells expressing the target molecule (mesothelin, MSLN), the AB-loop sequence of the virus clones converged to one dominant sequence and a novel MSLN-targeting sequence was isolated. The virus with the isolated motif showed selective infectivity to MSLN-positive cells in vitro. In vivo, it exhibited a selective and potent antitumor effect resulted from the viral replication in MSLN-positive xenografts. The ISOAd is a novel class of oncolytic Ad, which has selectivity at the step of transduction. The selectivity at the stage of infection can open new perspectives in oncolytic Ad therapy for various diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23032977      PMCID: PMC3538312          DOI: 10.1038/mt.2012.205

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  32 in total

1.  Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions.

Authors:  D A Einfeld; R Schroeder; P W Roelvink; A Lizonova; C R King; I Kovesdi; T J Wickham
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Steps toward mapping the human vasculature by phage display.

Authors:  Wadih Arap; Mikhail G Kolonin; Martin Trepel; Johanna Lahdenranta; Marina Cardó-Vila; Ricardo J Giordano; Paul J Mintz; Peter U Ardelt; Virginia J Yao; Claudia I Vidal; Limor Chen; Anne Flamm; Heli Valtanen; Lisa M Weavind; Marshall E Hicks; Raphael E Pollock; Gregory H Botz; Corazon D Bucana; Erkki Koivunen; Dolores Cahill; Patricia Troncoso; Keith A Baggerly; Rebecca D Pentz; Kim-Anh Do; Christopher J Logothetis; Renata Pasqualini
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

3.  Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus.

Authors:  S A Nicklin; D J Von Seggern; L M Work; D C Pek; A F Dominiczak; G R Nemerow; A H Baker
Journal:  Mol Ther       Date:  2001-12       Impact factor: 11.454

4.  The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses.

Authors:  Kaori Suzuki; Ramón Alemany; Masato Yamamoto; David T Curiel
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

5.  Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae.

Authors:  P W Roelvink; G Mi Lee; D A Einfeld; I Kovesdi; T J Wickham
Journal:  Science       Date:  1999-11-19       Impact factor: 47.728

6.  Targeting the prostate for destruction through a vascular address.

Authors:  Wadih Arap; Wolfgang Haedicke; Michele Bernasconi; Renate Kain; Daniel Rajotte; Stanislaw Krajewski; H Michael Ellerby; Dale E Bredesen; Renata Pasqualini; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

7.  Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer.

Authors:  Masato Yamamoto; Julia Davydova; Minghui Wang; Gene P Siegal; Victor Krasnykh; Selwyn M Vickers; David T Curiel
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

8.  A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

Authors:  J Randolph Hecht; Rudolph Bedford; James L Abbruzzese; Sandeep Lahoti; Tony R Reid; Roy M Soetikno; David H Kirn; Scott M Freeman
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

9.  Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.

Authors:  T Nishimoto; K Yoshida; Y Miura; A Kobayashi; H Hara; S Ohnami; K Kurisu; T Yoshida; K Aoki
Journal:  Gene Ther       Date:  2009-02-19       Impact factor: 5.250

10.  A tumor-homing peptide with a targeting specificity related to lymphatic vessels.

Authors:  Pirjo Laakkonen; Kimmo Porkka; Jason A Hoffman; Erkki Ruoslahti
Journal:  Nat Med       Date:  2002-06-10       Impact factor: 53.440

View more
  13 in total

Review 1.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 2.  Oncolytic viruses: From bench to bedside with a focus on safety.

Authors:  Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Development of a novel efficient method to construct an adenovirus library displaying random peptides on the fiber knob.

Authors:  Yuki Yamamoto; Naoko Goto; Kazuki Miura; Kenta Narumi; Shumpei Ohnami; Hiroaki Uchida; Yoshiaki Miura; Masato Yamamoto; Kazunori Aoki
Journal:  Mol Pharm       Date:  2014-01-24       Impact factor: 4.939

Review 4.  The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer

Authors:  Mizuho Sato-Dahlman; Masato Yamamoto
Journal:  Curr Cancer Drug Targets       Date:  2018       Impact factor: 3.428

Review 5.  Gene and virotherapy for hematological malignancies.

Authors:  Evidio Domingo-Musibay; Masato Yamamoto
Journal:  Int J Hematol       Date:  2016-06-11       Impact factor: 2.490

Review 6.  Retargeting adenoviruses for therapeutic applications and vaccines.

Authors:  Michael A Barry; Jeffrey D Rubin; Shao-Chia Lu
Journal:  FEBS Lett       Date:  2020-02-03       Impact factor: 4.124

Review 7.  Intestinal Microbiota-A Promising Target for Antiviral Therapy?

Authors:  Mengling Yang; Yang Yang; Qingnan He; Ping Zhu; Mengqi Liu; Jiahao Xu; Mingyi Zhao
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

8.  Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds.

Authors:  Michael Behr; Johanna K Kaufmann; Patrick Ketzer; Sarah Engelhardt; Martin Mück-Häusl; Pamela M Okun; Gabriele Petersen; Frank Neipel; Jessica C Hassel; Anja Ehrhardt; Alexander H Enk; Dirk M Nettelbeck
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

Review 9.  Recent advances in genetic modification of adenovirus vectors for cancer treatment.

Authors:  Yuki Yamamoto; Masaki Nagasato; Teruhiko Yoshida; Kazunori Aoki
Journal:  Cancer Sci       Date:  2017-05-07       Impact factor: 6.716

Review 10.  Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts.

Authors:  Jing Li Huang; Christopher J LaRocca; Masato Yamamoto
Journal:  Biomedicines       Date:  2016-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.